2017
DOI: 10.1016/j.virusres.2016.09.015
|View full text |Cite
|
Sign up to set email alerts
|

Synergistic reactivation of latent HIV-1 provirus by PKA activator dibutyryl-cAMP in combination with an HDAC inhibitor

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
17
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(17 citation statements)
references
References 27 publications
0
17
0
Order By: Relevance
“…Because our phosphoproteomic analysis identified PKA, also known as cAMP-dependent protein kinase, as a novel kinase active during BTV infection, we wanted to validate and assess its role during BTV replication. To this end, we used the PKA inhibitor H89 ( 34 ) and the PKA activator Dibutyryl-cAMP ( 35 ) to explore the effects of PKA inhibition and activation on BTV replication. Although HeLa cells support BTV replication successfully and were chosen for the initial phosphoproteomic characterization of BTV infection, because of the superior annotation of the human proteome and availability of analysis tools ( Fig.…”
Section: Resultsmentioning
confidence: 99%
“…Because our phosphoproteomic analysis identified PKA, also known as cAMP-dependent protein kinase, as a novel kinase active during BTV infection, we wanted to validate and assess its role during BTV replication. To this end, we used the PKA inhibitor H89 ( 34 ) and the PKA activator Dibutyryl-cAMP ( 35 ) to explore the effects of PKA inhibition and activation on BTV replication. Although HeLa cells support BTV replication successfully and were chosen for the initial phosphoproteomic characterization of BTV infection, because of the superior annotation of the human proteome and availability of analysis tools ( Fig.…”
Section: Resultsmentioning
confidence: 99%
“…Finally, we note that additional latency reversal mechanisms by these agents may remain undetected. For example, we previously described alotaketal C as an LRA of the PKC activator class [ 14 ], but it is additionally reported to function as an activator of cyclic AMP signaling [ 20 ], which may also modulate HIV-1 latency reversal [ 40 , 41 ].…”
mentioning
confidence: 99%
“…However, studies have also questioned their efficacy in HIV-1 reservoirs in vivo 35 , 36 . Therefore, recent publications have underscored the need for using different combinations of LRAs to enable potent latency-reactivation 37 , 38 . We investigated whether coexposure to the ASC-CM can increase the LRA efficacy of vorinostat (SAHA) and panobinostat (Pano) (Fig.…”
Section: Resultsmentioning
confidence: 99%
“…Therefore, factors secreted by MSCs, or specific signaling pathways activated by primary human MSCs, may provide novel and superior strategies to activate the latent tissue reservoirs, and will no doubt be of more physiologic significance 33 , 38 , 52 . In this respect, several laboratories have shown that the combination of LRAs with different mechanisms of action may be more effective and less toxic in vivo 37 , 38 , 53 . Coexposure to bryostatin (a PKC-agonist) and panobinostat (a HDACi) provided better latency reactivation, as compared to each of these agents alone 53 .…”
Section: Discussionmentioning
confidence: 99%